May 19th, 2020
TelAbortion Media Toolkit
Apr 28th, 2020
New York Times article: Abortion by Telemedicine: A Growing Option as Access to Clinics Wanes
Apr 14th, 2020
No-Test Medication Abortion: A Sample Protocol for Increasing Access During a Pandemic and Beyond
Apr 9th, 2020
COVID-19
Mar 16th, 2020
A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation
Sensitivity and specificity of placental proteins for gestational age screening: An exploratory study
A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries
Mifepristone pretreatment followed by misoprostol 200mcg buccal for the medical management of intrauterine fetal death at 14-28 weeks: A randomized, placebo-controlled, double blind trial
Mar 10th, 2020
High fever after sublingual administration of misoprostol for treatment of post-partum haemorrhage: a hospital-based, prospective observational study in Argentina
Feb 20th, 2020
TelAbortion Webinar March 11 2020, 3-4pm EST
Feb 4th, 2020
Newsletter February 2020
Dec 9th, 2019
Gynuity - RHSC Webinar December 12
Oct 2nd, 2019
Mifepristone's multiple reproductive health indications
Sep 26th, 2019
Newsletter September 2019
Sep 25th, 2019
Medical abortion telemedicine pilot launched in Mexico
Sep 19th, 2019
The effectiveness and safety of introducing condom-catheter uterine balloon tamponade for postpartum haemorrhage
Sep 17th, 2019
The correlation of postpartum blood loss and poor clinical outcomes
Mar 8th, 2019
Newsletter March 2019
Mar 6th, 2019
Gynuity's TelAbortion project featured in The New Yorker
Dec 14th, 2018
Newsletter December 2018
Oct 23rd, 2018
CNN coverage of Gynuity's Telabortion study
Oct 3rd, 2018
Webinar, October 3 – IPPF’s new medical abortion commodities database
Sep 28th, 2018
Newsletter September 2018
Jul 19th, 2018
The Atlantic features Gynuity research in an article about online abortion pills in the US
May 22nd, 2018
Newsletter May 2018
